Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells
Rituximab is a commonly used chemotherapeutic drug for patients with aggressive lymphomas, such as non-Hodgkin’s lymphoma (NHL). Currently, the combination of Rituximab and chemotherapy (R-CHOP) stands as the most prevalent first-line therapy for NHL. Nevertheless, the development of new therapeutic...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2024-02-01
|
| Seri Bilgileri: | Frontiers in Oncology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1339584/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|